Oral ivermectin is a systemic antiparasitic medication from the macrocyclic lactone class, widely used for the treatment of scabies, strongyloidiasis, and resistant lice infestations. As the primary peroral formulation of ivermectin, it delivers systemic exposure required for deep‑tissue and disseminated parasitic infections. The branded version, Stromectol, represents the original FDA‑approved oral formulation, while generic ivermectin tablets provide equivalent pharmacologic activity and therapeutic outcomes.
Unlike topical ivermectin, which is designed for dermatologic conditions such as rosacea and Demodex‑associated inflammation, oral ivermectin acts systemically and is indicated for parasitic infections requiring whole‑body distribution. This page provides a complete scientific overview of oral ivermectin, including pharmacology, clinical indications, safety, and formulation‑specific characteristics. Explore related sections: Stromectol, Ivermectin oral vs topical, Ivermectin price.
Oral ivermectin is a broad‑spectrum antiparasitic medication belonging to the macrocyclic lactone class. It is used worldwide for systemic parasitic infections, particularly those caused by nematodes and ectoparasites. As an orally administered agent, it provides full‑body therapeutic coverage, making it the preferred formulation for conditions where parasites reside in deeper tissues or circulate through the bloodstream.
Pharmacologically, oral ivermectin works by selectively binding to parasite glutamate‑gated chloride channels, increasing membrane permeability and causing paralysis and death of the parasite. This selectivity ensures a strong safety margin in humans while maintaining high efficacy against target organisms.
Oral ivermectin is available in two standard strengths: 3 mg and 6 mg tablets. These strengths support weight‑based dosing strategies commonly used in clinical practice. The 3 mg formulation is widely recognized as the traditional tablet strength, while the 6 mg version offers a higher‑dose alternative that may reduce pill burden.
Both generic ivermectin and the branded formulation Stromectol contain the same active ingredient and demonstrate equivalent therapeutic effects. The primary differences lie in branding, packaging, and price. Generic ivermectin is typically more cost‑efficient, while Stromectol is the original branded product historically approved in multiple regions.
Oral ivermectin remains a cornerstone therapy for systemic parasitic infections such as scabies, strongyloidiasis, and resistant lice infestations. Its predictable pharmacokinetics, long half‑life, and proven clinical outcomes make it one of the most widely used antiparasitic agents in global medicine.
| Form | Strength | Route | Main Indications | Internal Link |
|---|---|---|---|---|
| Ivermectin 3 mg | 3 mg | Oral | Scabies, strongyloidiasis, lice | Ivermectin 3 mg |
| Ivermectin 6 mg | 6 mg | Oral | Scabies, strongyloidiasis, lice | Ivermectin 6 mg |
Oral ivermectin exerts its antiparasitic activity primarily through selective binding to glutamate‑gated chloride channels, a unique class of ion channels found in invertebrate nerve and muscle cells. This interaction increases chloride influx, leading to cellular hyperpolarization. Because these channels are absent in humans, the drug maintains a strong safety margin while delivering potent systemic activity. More details are available in Ivermectin MOA.
The resulting hyperpolarization causes paralysis of parasites, preventing feeding, attachment, and reproduction. In nematodes and ectoparasites, this paralysis is irreversible, ultimately leading to death. Oral ivermectin’s systemic distribution allows it to reach parasites located in deeper tissues, the bloodstream, or the gastrointestinal tract, making it effective for conditions such as strongyloidiasis and scabies.
Compared with topical formulations, oral ivermectin provides full‑body systemic exposure, enabling it to target parasites beyond the skin surface. Topical ivermectin, by contrast, acts locally within the epidermis and pilosebaceous units, making it suitable for dermatologic conditions such as rosacea and demodicosis. The systemic form does not rely on local skin penetration and therefore achieves broader antiparasitic coverage.
| Form | Primary Action | Distribution | Clinical Focus |
|---|---|---|---|
| Oral ivermectin | Glutamate‑gated chloride channel activation → systemic parasite paralysis | Systemic (bloodstream, tissues) | Strongyloidiasis, scabies, systemic parasitic infections |
| Topical ivermectin | Local antiparasitic + anti‑inflammatory effects | Localized to skin and follicles | Rosacea, demodex overgrowth, inflammatory skin conditions |
Oral ivermectin demonstrates a well‑characterized pharmacokinetic profile shaped by its lipophilicity, metabolic pathway, and food‑dependent absorption. After ingestion, the drug is absorbed in the gastrointestinal tract, with fat‑rich meals significantly increasing bioavailability. This enhancement occurs because ivermectin is highly lipophilic, allowing improved solubilization and uptake when co‑administered with dietary fats. Clinically, this results in higher systemic exposure compared with fasting administration. For a deeper overview of PK principles, see Ivermectin PK.
Once absorbed, ivermectin exhibits extensive distribution due to its strong affinity for lipid‑rich tissues. Its high lipophilicity enables penetration into peripheral compartments, supporting prolonged antiparasitic activity. The drug is also highly protein‑bound, which contributes to a long elimination half‑life and sustained systemic levels after a single dose.
Oral ivermectin undergoes hepatic metabolism primarily via CYP3A4, with minor contributions from other oxidative pathways. This metabolic dependence means that strong CYP3A4 inhibitors or inducers may influence systemic exposure, although clinical significance varies by context. The metabolites formed are generally less active and are prepared for biliary elimination.
Excretion occurs mainly through the biliary–fecal route, with minimal renal clearance. The prolonged elimination half‑life supports intermittent dosing schedules and contributes to the drug’s sustained antiparasitic effect. Together, these PK characteristics explain why oral ivermectin is effective for systemic parasitic infections requiring deep tissue penetration and long‑lasting activity.
| Parameter | Value / Description |
|---|---|
| Absorption | Enhanced with high‑fat meals; increased bioavailability |
| Distribution | Highly lipophilic; extensive tissue penetration; strong protein binding |
| Metabolism | Primarily via CYP3A4; oxidative hepatic pathways |
| Elimination | Biliary–fecal excretion; long elimination half‑life |
Oral ivermectin is a systemic antiparasitic agent widely used in global clinical practice for the treatment of internal and external parasitic infections. Its broad distribution, long half‑life, and ability to reach deep tissue compartments make it the preferred formulation for infections that extend beyond the epidermis. The following sections outline the major therapeutic indications and clinical scenarios where oral ivermectin is favored over topical alternatives.
Oral ivermectin is considered a first‑line or adjunctive therapy for several systemic and cutaneous parasitic diseases. Its mechanism of action—selective activation of parasite glutamate‑gated chloride channels—allows rapid paralysis and elimination of target organisms. Below are the primary infections for which oral ivermectin is clinically utilized.
Scabies. Oral ivermectin is widely used for classic, crusted, and treatment‑resistant scabies. It is especially valuable when topical agents fail, when widespread infestation is present, or when applying creams is impractical. More details are available on Ivermectin for scabies.
Strongyloidiasis. As a systemic nematode infection, strongyloidiasis requires a medication capable of reaching deep tissues and circulating larvae. Oral ivermectin is the preferred therapy due to its systemic distribution and proven efficacy. See Ivermectin for strongyloides for expanded clinical context.
Lice infestations. While topical pediculicides are commonly used, oral ivermectin is effective for resistant lice, recurrent infestations, or situations where topical application is not feasible. Systemic action ensures eradication even when parasites are difficult to reach. Additional information is available on Ivermectin for lice.
Although topical ivermectin is effective for localized dermatologic conditions, the oral form is superior in several clinical scenarios. Its systemic distribution allows it to target parasites throughout the body, making it indispensable for infections that extend beyond the skin surface.
Generalized or systemic infections. Conditions such as strongyloidiasis or crusted scabies require systemic therapy because parasites inhabit deeper tissues or produce widespread infestation. Oral ivermectin provides the necessary full‑body exposure.
Ineffectiveness of topical treatments. When topical agents fail due to resistance, improper application, or severe disease burden, oral ivermectin offers a reliable alternative with predictable systemic activity.
Inability to use topical formulations. Patients with extensive skin involvement, mobility limitations, or dermatologic hypersensitivity may be unable to apply topical medications effectively. Oral ivermectin bypasses these limitations entirely.
| Form | Primary Use | Clinical Scenarios |
|---|---|---|
| Oral ivermectin | Systemic antiparasitic therapy | Scabies, strongyloidiasis, resistant lice; generalized infections; topical failure |
| Topical ivermectin | Localized dermatologic therapy | Rosacea, demodex overgrowth, mild localized infestations |
Oral ivermectin is used in standardized, guideline‑based regimens that rely on weight‑based calculations and fixed‑interval dosing. These approaches are applied by clinicians for a range of parasitic infections requiring systemic therapy. The following information summarizes commonly referenced principles without providing individualized medical recommendations. These patterns reflect how oral ivermectin is typically administered in clinical practice.
Standard informational regimens. Oral ivermectin is generally administered as a single systemic dose or as part of a two‑dose schedule depending on the infection type. For conditions such as scabies, strongyloidiasis, and resistant lice, clinicians often use structured intervals to ensure adequate exposure across parasite life cycles. These regimens are based on established medical guidelines and are not tailored to individual patient characteristics.
Dosing intervals. Many parasitic organisms have multi‑stage life cycles, which is why interval‑based dosing is frequently used. A second dose may be administered after a defined period to target newly emerged parasites that were not susceptible during the initial exposure. This interval‑based strategy is a standard informational pattern across antiparasitic therapy.
Repeat courses. In some clinical scenarios—such as persistent infestations, high parasite burden, or incomplete response—repeat courses may be used. These follow structured timelines and are determined by clinical assessment rather than patient‑directed adjustments. The goal of repeated dosing is to ensure full eradication across all developmental stages of the parasite.
Influence of body weight. Oral ivermectin is traditionally administered using weight‑based calculations. This ensures predictable systemic exposure and consistent pharmacokinetics across individuals. Weight‑based principles are especially important for systemic infections such as strongyloidiasis, where adequate drug levels are required to reach tissue‑dwelling larvae. These calculations follow standardized medical formulas and are not individualized within this informational overview.
| Condition | Pattern | Interval | Notes |
|---|---|---|---|
| Scabies | Single systemic dose ± second dose | Second dose after a defined interval | Used for classic, crusted, or resistant cases |
| Strongyloidiasis | Systemic dose based on weight | May involve repeat dosing | Targets tissue‑dwelling larvae |
| Lice | Systemic dose with optional repeat | Repeat after a defined interval | Used when topical agents are ineffective |
Oral ivermectin has a well‑established safety profile, but its systemic activity requires attention to specific contraindications and precautionary factors. These considerations help clinicians determine when the medication may pose increased risk or require additional monitoring. A broader overview of safety principles is available in Ivermectin oral — precautions.
Oral ivermectin is generally avoided in individuals with known hypersensitivity to macrocyclic lactones or any component of the formulation. Because the drug undergoes hepatic metabolism, caution is applied in cases of significant liver impairment, where altered clearance may increase systemic exposure. Although rare, neurological adverse reactions have been reported in individuals with impaired blood–brain barrier function, making such conditions a relative contraindication in some clinical contexts.
Certain groups require additional consideration due to altered pharmacokinetics or increased susceptibility to adverse effects. These include individuals with severe systemic illness, frail older adults, and patients with conditions that may compromise drug distribution or metabolism. In endemic regions, individuals with high Loa loa microfilarial loads may be at risk for severe reactions due to rapid parasite killing, making screening essential in high‑prevalence areas. Pregnant or breastfeeding individuals are typically evaluated cautiously, as systemic exposure may affect fetal or neonatal development.
Oral ivermectin is metabolized primarily through CYP3A4, making drug–drug interactions a key precaution. Strong CYP3A4 inhibitors may increase ivermectin plasma concentrations, potentially enhancing systemic effects. Examples include certain antifungals, macrolide antibiotics, and antiretroviral agents. Conversely, CYP3A4 inducers may reduce systemic exposure, potentially decreasing antiparasitic efficacy. Because ivermectin is also a substrate of P‑glycoprotein, combined inhibition of CYP3A4 and P‑gp may further elevate systemic levels, requiring heightened clinical awareness.
| Category | Description |
|---|---|
| General contraindications | Hypersensitivity, severe hepatic impairment, compromised blood–brain barrier |
| Special populations | Pregnancy, breastfeeding, frail adults, high Loa loa microfilarial burden |
| CYP3A4 interactions | Increased exposure with strong inhibitors; reduced exposure with inducers |
Oral ivermectin has a systemic pharmacokinetic profile influenced by metabolic enzymes, transport proteins, and co‑administered agents. Understanding these interactions is essential for predicting changes in systemic exposure and potential safety considerations. A full interaction overview is available in Ivermectin oral interactions.
Oral ivermectin is metabolized primarily by CYP3A4, making it susceptible to interactions with agents that inhibit or induce this enzyme. Strong CYP3A4 inhibitors—such as certain azole antifungals, macrolide antibiotics, and antiretroviral medications—may increase systemic ivermectin concentrations. This elevation can enhance pharmacologic effects and may increase the likelihood of adverse reactions. Conversely, CYP3A4 inducers may reduce ivermectin levels, potentially lowering antiparasitic efficacy. These interactions are mechanistic and informational, reflecting how metabolic pathways influence systemic exposure.
Ivermectin is also a substrate of P‑glycoprotein, a key efflux transporter that limits drug penetration into sensitive tissues. Inhibition of P‑gp may increase ivermectin distribution, including potential elevation of central nervous system exposure. Agents such as certain calcium channel blockers, immunosuppressants, and macrolides may influence P‑gp activity. Combined CYP3A4 and P‑gp inhibition can have an additive effect on systemic levels, making transporter interactions an important consideration in informational pharmacology.
While ivermectin does not have a direct pharmacokinetic interaction with alcohol, concurrent use may increase the likelihood of overlapping side effects such as dizziness, fatigue, or gastrointestinal discomfort. Alcohol may also influence hepatic metabolism indirectly, which is relevant given ivermectin’s reliance on CYP3A4 pathways. These considerations are informational and reflect general principles of combining systemic medications with alcohol.
Oral ivermectin may be used alongside other antiparasitic agents in certain clinical scenarios. However, combining multiple anthelmintics can influence overall parasite‑killing dynamics and may increase the likelihood of additive side effects. Drugs such as albendazole or mebendazole may share metabolic pathways or exert overlapping pharmacodynamic effects. These combinations are typically guided by structured medical protocols rather than patient‑directed adjustments.
| Interaction Type | Description |
|---|---|
| CYP3A4 inhibitors | Increase systemic exposure; may enhance pharmacologic effects |
| P‑gp modulators | Alter tissue distribution; may affect CNS penetration |
| Alcohol | May increase overlapping side effects; informational caution |
| Anthelmintics | Potential additive effects; used in structured combination protocols |
Oral ivermectin is generally well tolerated, with most adverse effects being mild and transient. Because the medication acts systemically, its safety profile reflects both pharmacologic effects and the body’s response to parasite elimination. A broader overview of safety considerations is available in Ivermectin general safety. The following sections summarize common, rare, and parasite‑load–dependent reactions.
Frequently reported adverse effects are typically mild and self‑limiting. These include dizziness, fatigue, headache, nausea, abdominal discomfort, and diarrhea. Some individuals may experience transient skin reactions such as itching or mild rash, which often reflect the body’s inflammatory response to dying parasites rather than a direct drug effect. These reactions usually resolve without intervention and are considered part of the expected tolerability profile of systemic antiparasitic therapy.
Rare adverse events may include hypotension, tachycardia, or more pronounced neurological symptoms such as confusion or ataxia. These effects are uncommon and often associated with underlying conditions that alter drug distribution or metabolism. In individuals with compromised blood–brain barrier function, ivermectin may reach higher central nervous system concentrations, increasing the likelihood of neurological symptoms. Such cases are infrequent and typically occur in specific clinical contexts.
In individuals with high parasite burden, particularly in infections involving microfilariae, systemic reactions may occur due to rapid parasite death. These Mazzotti‑type reactions can include fever, lymph node swelling, joint pain, intense itching, and skin inflammation. Although uncomfortable, these reactions reflect the immune system’s response to large‑scale parasite clearance rather than direct drug toxicity. They are more common in endemic regions or in infections with high microfilarial loads and are well documented in antiparasitic pharmacology.
| Category | Description |
|---|---|
| Common effects | Dizziness, headache, nausea, abdominal discomfort, mild rash |
| Rare effects | Hypotension, tachycardia, neurological symptoms in susceptible individuals |
| Mazzotti‑type reactions | Fever, lymphadenopathy, pruritus, inflammatory response to parasite death |
Oral and topical ivermectin share the same active molecule but differ significantly in mechanism, distribution, indications, and systemic exposure. These distinctions determine when each formulation is preferred in clinical practice. A full comparative overview is available on Ivermectin oral vs topical.
Both formulations act on glutamate‑gated chloride channels, causing paralysis and death of parasites. However, oral ivermectin provides systemic activity, reaching parasites in deeper tissues and the bloodstream. Topical ivermectin acts locally within the epidermis and pilosebaceous units, combining antiparasitic and anti‑inflammatory effects. This makes the topical form particularly effective for dermatologic conditions such as rosacea and demodicosis.
Oral ivermectin is used for systemic or widespread parasitic infections, including scabies, strongyloidiasis, and resistant lice. Its systemic distribution allows it to target parasites beyond the skin surface. Topical ivermectin is indicated for localized skin conditions, especially inflammatory dermatoses associated with Demodex mites. It is not suitable for systemic infections because it does not achieve therapeutic plasma levels.
Oral ivermectin typically produces a rapid systemic effect, especially in infections with circulating larvae or deep‑tissue involvement. Topical ivermectin acts more gradually, with visible improvement often occurring over days to weeks, depending on the dermatologic condition. The difference in onset reflects systemic versus localized drug distribution.
Oral ivermectin results in full‑body systemic exposure, influenced by CYP3A4 metabolism, P‑glycoprotein transport, and food‑dependent absorption. This systemic load is essential for treating internal parasites but requires attention to interactions and contraindications. Topical ivermectin has minimal systemic absorption, making it suitable for patients who require localized therapy with low systemic risk.
| Parameter | Oral ivermectin | Topical ivermectin |
|---|---|---|
| Mechanism | Systemic antiparasitic action via glutamate‑gated chloride channels | Local antiparasitic + anti‑inflammatory skin action |
| Indications | Scabies, strongyloidiasis, resistant lice, systemic infections | Rosacea, demodicosis, localized skin infestations |
| Speed of action | Rapid systemic effect | Gradual local improvement |
| Systemic load | High; influenced by CYP3A4 and P‑gp | Minimal; low systemic absorption |
Oral ivermectin is available in two primary forms: generic ivermectin tablets and the branded formulation Stromectol. Both contain the same active ingredient—ivermectin—and deliver equivalent antiparasitic activity. However, they differ in branding, regulatory positioning, pricing, and certain formulation characteristics. A broader comparison is available on Stromectol and Stromectol price.
Generic oral ivermectin and Stromectol share identical pharmacodynamic properties, including their mechanism of action on glutamate‑gated chloride channels and their systemic antiparasitic effect. Stromectol is the original branded product historically approved in multiple regions, while generic ivermectin is produced by various manufacturers after patent expiration. The therapeutic equivalence between the two is well established, with no clinically meaningful differences in efficacy or safety.
Both formulations exhibit similar oral bioavailability, influenced by the same factors: lipophilicity, CYP3A4 metabolism, and increased absorption when taken with high‑fat meals. Minor excipient differences between manufacturers do not significantly affect systemic exposure. As a result, generic ivermectin and Stromectol achieve comparable plasma concentrations under standard dosing conditions.
The most notable distinction is cost. Stromectol, as a branded medication, is typically priced significantly higher than generic ivermectin tablets. The price gap varies by region, manufacturer, and supply chain factors, but generics consistently offer a more economical option. This makes generic ivermectin the preferred choice in most clinical and commercial settings, while Stromectol may be selected in markets where brand‑name assurance or specific regulatory approvals are prioritized.
| Parameter | Generic ivermectin | Stromectol |
|---|---|---|
| Active ingredient | Ivermectin | Ivermectin |
| Bioavailability | Equivalent systemic exposure | Equivalent systemic exposure |
| Regulatory status | Multiple manufacturers; generic approvals | Original branded formulation |
| Price | Lower cost; widely accessible | Higher cost; brand‑name premium |
Oral ivermectin is frequently compared with other antiparasitic and antimicrobial agents due to its broad systemic activity and established role in treating nematode and ectoparasitic infections. While each alternative—permethrin, albendazole, mebendazole, and doxycycline— has its own therapeutic niche, ivermectin’s systemic distribution and unique mechanism of action often make it the preferred option in specific clinical scenarios. Expanded comparisons are available on Ivermectin vs Permethrin, Ivermectin vs Albendazole, and Ivermectin vs Doxycycline.
Permethrin is a topical pyrethroid used primarily for scabies and lice. Unlike oral ivermectin, it acts locally on parasite sodium channels and does not provide systemic coverage. Ivermectin is preferred when infestations are widespread, resistant to topical therapy, or when topical application is impractical. Permethrin remains first‑line for many mild cases, but oral ivermectin offers broader reach and convenience in severe or crusted scabies.
Albendazole is a systemic benzimidazole effective against a wide range of helminths. It works by inhibiting microtubule formation, disrupting parasite glucose uptake. While albendazole is preferred for many intestinal helminth infections, oral ivermectin is superior for strongyloidiasis and ectoparasitic infestations. In some protocols, both drugs are used together for synergistic coverage.
Mebendazole is another benzimidazole with strong activity against intestinal worms such as pinworm, whipworm, and roundworm. Its poor systemic absorption limits its use to gastrointestinal parasites. Oral ivermectin, with its systemic distribution, is preferred for infections involving tissue‑migrating larvae or ectoparasites.
Doxycycline is a tetracycline antibiotic with antiparasitic activity against filarial organisms through its action on Wolbachia endosymbionts. It is used in long‑course regimens for onchocerciasis and lymphatic filariasis. Oral ivermectin provides rapid parasite clearance, while doxycycline offers long‑term sterilizing effects. The two are often complementary rather than interchangeable.
| Drug | Mechanism | Primary Use | Key Difference |
|---|---|---|---|
| Permethrin | Topical sodium‑channel disruption | Scabies, lice | Local action only; ivermectin provides systemic coverage |
| Albendazole | Microtubule inhibition | Intestinal helminths | Albendazole is GI‑focused; ivermectin targets systemic parasites |
| Mebendazole | Microtubule disruption | Pinworm, whipworm, roundworm | Poor systemic absorption; ivermectin reaches tissues |
| Doxycycline | Anti‑Wolbachia antibiotic | Filarial infections | Slow sterilizing effect vs ivermectin’s rapid parasite clearance |
The cost of oral ivermectin varies widely depending on formulation, manufacturer, region, and supply chain factors. The market includes both generic ivermectin tablets and the branded formulation Stromectol, each occupying a different pricing segment. A broader overview of pricing trends is available on Ivermectin price and Stromectol price.
Generic oral ivermectin is typically the most cost‑efficient option. Because it is manufactured by multiple producers, competition keeps prices significantly lower than branded alternatives. Generic tablets (3 mg and 6 mg) are widely available in international markets, with pricing influenced by production volume, regional regulations, and wholesale distribution. For most commercial and clinical settings, generics represent the preferred choice due to their affordability and therapeutic equivalence.
Stromectol, the original branded ivermectin formulation, is consistently priced higher. Its cost reflects brand recognition, historical regulatory approvals, and limited manufacturer competition. In many regions, Stromectol may be several times more expensive than generic ivermectin, making it a premium option rather than a standard choice. Despite identical active ingredients, the brand‑name premium remains a major commercial distinction.
Several variables affect the final retail price of oral ivermectin. These include dosage strength (3 mg vs 6 mg), pack size, manufacturer, country‑specific regulations, pharmacy markups, and supply chain stability. Market demand, import restrictions, and raw material availability can also influence fluctuations. Branded products like Stromectol are more sensitive to regulatory and distribution factors, while generics benefit from broader manufacturing diversity.
| Formulation | Strength | Typical Price Range |
|---|---|---|
| Generic ivermectin | 3 mg / 6 mg | Lower cost; varies by region |
| Stromectol | 3 mg | Higher cost; brand‑name premium |